{
    "clinical_study": {
        "@rank": "75747", 
        "acronym": "CKD-519 FIH", 
        "arm_group": [
            {
                "arm_group_label": "CKD-519 25mg", 
                "arm_group_type": "Experimental", 
                "description": "CKD-519 25mg or placebo"
            }, 
            {
                "arm_group_label": "CKD-519 50mg", 
                "arm_group_type": "Experimental", 
                "description": "CKD-519 50mg or placebo"
            }, 
            {
                "arm_group_label": "CKD-519 100mg", 
                "arm_group_type": "Experimental", 
                "description": "CKD-519 100mg or  placebo"
            }, 
            {
                "arm_group_label": "CKD-519 200mg", 
                "arm_group_type": "Experimental", 
                "description": "CKD-519 200mg or placebo"
            }, 
            {
                "arm_group_label": "CKD-519 400mg", 
                "arm_group_type": "Experimental", 
                "description": "CKD-519 400mg or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety/tolerability and\n      pharmacokinetics/pharmacodynamics of CKD-519."
        }, 
        "brief_title": "Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519", 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Between 19 aged and 55 aged in healthy adult\n\n          2. Body weight more than 55kg in male, 50kg in female\n\n          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)\n\n          4. If female, must include more than one among the items\n\n               -  The menopause(there is no natural menses for at least 2 years)\n\n               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or\n                  other methods of infertility condition\n\n          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use\n             condoms and do not sperm donation until two months during clinical trials and after\n             the final dosage of investigational products\n\n          6. Those who fully understand about this clinical trials after enough hearing, and then\n             decided to join the clinical trials by themselves and to comply with the precautions\n             written consent\n\n        Exclusion Criteria:\n\n          1. Have clinically significant disease that hepatobiliary system(severe hepatic\n             impairment, etc), kidney(severe renal impairment, etc), nervous system, immune\n             system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular\n             system(heart failure, etc) or mental illness, or a history of mental disease.\n\n          2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's\n             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)\n\n          3. Hypersensitivity reaction  or clinically significant hypersensitivity reaction in the\n             history of drugs or additives.\n\n          4. An impossible one who participates in clinical trial including screening\n             tests(medical history taking, BP, 12-lead ECG, physical examination, blood&urine\n             laboratory test result) before 28 days the taking investigational Products.\n\n          5. Defined by the following laboratory parameters\n\n               -  AST, ALT>1.25* upper limit of normal range\n\n               -  Total bilirubin>1.5* upper limit of normal range\n\n               -  CPK>1.5* upper limit of normal range\n\n               -  eGFR(using by MDRD method)<60mL/min/1.73m2\n\n          6. Sitting SBP>150mmHg or <90mmHg, sitting DBP>100mmHg or <50mmHg, after 5 minutes\n             break.\n\n          7. Drug abuse or have a history of drug abuse showes a positive for urine drug test.\n\n          8. Pregnant or lactating women.\n\n          9. A heavy caffeine consumer(caffeine>5 cups/day), alcohol consumer(alcohol>210g/week),\n             or smoker(cigarette>10 cigarettes/day)\n\n         10. Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days\n             before the beginning of study treatment but investigator determine that the taking\n             drug affect this study or could affect the safety of subjects.\n\n         11. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates\n             etc.) within 30 days.\n\n         12. Taking foods containing grapefruit within 7 days before the beginning of study\n             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days\n             before the beginning of study treatment)\n\n         13. Subject who treated with any investigational drugs within 60 days before the\n             beginning of study treatment(However, biologicals applies for 90 days, but can be\n             based on a more extended period of time by considering the half-life)\n\n         14. Previously donate whole blood within 60 days or component blood within 30 days.\n\n         15. An impossible one who participants in clinical trial by investigator's decision\n             including laboratory test result or another reason.\n\n         16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156544", 
            "org_study_id": "148HPS14001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CKD-519 25mg", 
                    "CKD-519 50mg", 
                    "CKD-519 100mg", 
                    "CKD-519 200mg", 
                    "CKD-519 400mg"
                ], 
                "intervention_name": "CKD-519", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "CKD-519 25mg", 
                    "CKD-519 50mg", 
                    "CKD-519 100mg", 
                    "CKD-519 200mg", 
                    "CKD-519 400mg"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "minsupark@yuhs.ac", 
                "last_name": "Min-Su Park, Ph.D", 
                "phone": "+82-2-2228-0400"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Seodaemun-gu", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }, 
            "investigator": {
                "last_name": "Min-Su Park, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers", 
        "overall_contact": {
            "email": "minsupark@yuhs.ac", 
            "last_name": "Min-Su Park, Ph.D", 
            "phone": "+82-2-2228-0400"
        }, 
        "overall_official": {
            "affiliation": "Severance Hospital", 
            "last_name": "Min-Su Park, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "AUC0-last of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "AUC0-\u221e of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "Tmax of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "t1/2 of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "CL/F of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }, 
            {
                "measure": "Vd/F of CKD-519", 
                "safety_issue": "No", 
                "time_frame": "0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156544"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "CETP activity", 
            "safety_issue": "No", 
            "time_frame": "0(Predose), 0.5, 1, 2, 4, 8, 18, 24, 48, 72, 96, 120, 144, 168"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}